DRYTEC Drug Patent Profile

When do Drytec patents expire, and when can generic versions of Drytec launch?

Drytec is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in DRYTEC is technetium tc-99m sodium pertechnetate generator. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m sodium pertechnetate generator profile page.

Summary for DRYTEC

US Patents:	0
Applicants:	1
NDAs:	1
Drug Prices:	Drug price information for DRYTEC
DailyMed Link:	DRYTEC at DailyMed

See drug prices for DRYTEC

US Patents and Regulatory Information for DRYTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	DRYTEC	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS, ORAL	017693-002	Dec 13, 2013		DISCN	Yes	No
Ge Healthcare	DRYTEC	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS, ORAL	017693-001	Approved Prior to Jan 1, 1982		DISCN	No	No

DRYTEC Market Dynamics and Financial Trajectory

Last updated: August 23, 2026

DRYTEC is a molybdenum-99/technetium-99m generator used to produce technetium-99m for diagnostic nuclear medicine. It is not a conventional therapeutic drug. Its commercial performance depends on nuclear-reactor capacity, isotope logistics, hospital imaging volumes, manufacturing authorization, and supply reliability rather than on ordinary prescription demand.

Public disclosures do not report standalone DRYTEC revenue, operating profit, unit sales, or product-level forecasts. The financial trajectory is therefore best assessed through the economics of technetium-99m supply, the position of its manufacturer, regulatory barriers, and the competitive market for radiopharmaceutical generators.

What is DRYTEC and how does it generate revenue?

DRYTEC is a ^99Mo/^99mTc generator. Molybdenum-99 decays into technetium-99m, which is eluted from the generator at healthcare facilities and used to prepare diagnostic radiopharmaceuticals. Technetium-99m is used in procedures involving cardiac imaging, bone scans, renal imaging, hepatobiliary imaging, and other single-photon emission computed tomography applications.

The product generates revenue through recurring generator shipments to hospitals, radiopharmacies, and nuclear-medicine distributors. Revenue is tied to:

• Generator size and activity level.
• Delivery frequency and isotope half-life.
• Hospital and radiopharmacy procedure volumes.
• Regional reimbursement for diagnostic imaging.
• Reactor and processing availability.
• Transportation and handling requirements.
• Product registration in each jurisdiction.

Because molybdenum-99 has a half-life of approximately 66 hours and technetium-99m has a half-life of approximately six hours, the business requires tightly managed production and delivery schedules.[1]

What is the FDA and regulatory status of DRYTEC?

DRYTEC is primarily a non-U.S. and European-market product name. Its regulatory status depends on the jurisdiction and the specific marketing authorization holder. Public UK product information identifies DRYTEC as a ^99Mo/^99mTc generator supplied for the preparation of technetium-99m radiopharmaceuticals.[2]

The key regulatory characteristics are:

Regulatory issue	Commercial effect
Product authorization	Required for generator supply and elution use
Radioactive-material licensing	Required at the healthcare-facility level
Good manufacturing practice	Applies to generator production, assembly, quality control, and release
Pharmacopoeial compliance	Controls radionuclide purity, breakthrough, sterility, and performance
Transport regulation	Limits shipment timing and increases logistics costs
Reactor-source qualification	Creates dependence on approved ^99Mo suppliers
Local nuclear regulation	Can delay market entry even after medicinal-product approval

DRYTEC is not generally evaluated through the same pathway as a small-molecule prescription medicine. The commercial barrier is a combined medicinal-product, radioactive-material, manufacturing, and logistics framework.

How large is the technetium-99m market?

Technetium-99m remains the dominant diagnostic medical isotope by procedure volume. The market is commonly estimated at tens of millions of diagnostic procedures annually worldwide, although estimates differ by geography and methodology.[3]

Demand is supported by several factors:

1. Technetium-99m has favorable imaging characteristics, including a six-hour half-life and approximately 140 keV photon energy.
2. Hospitals have installed SPECT infrastructure and trained personnel.
3. Many technetium-based procedures are lower-cost alternatives to some PET or MRI examinations.
4. Technetium-based agents cover multiple clinical indications.
5. Generator supply supports facilities that do not operate an on-site cyclotron.

The market is mature rather than high-growth. Volume growth is generally linked to aging populations, cardiovascular disease, cancer diagnosis, hospital capacity, and substitution among imaging modalities.

What market dynamics affect DRYTEC demand?

Reactor concentration creates supply volatility

Most commercial ^99Mo originates from a limited group of research reactors and processing facilities. Reactor outages, maintenance, transport failures, target-processing problems, and geopolitical restrictions can create shortages.

The International Atomic Energy Agency has identified medical-isotope supply resilience as a continuing policy issue because the global ^99Mo supply chain has historically depended on aging reactors and concentrated processing capacity.[4]

For DRYTEC, supply interruptions can produce two opposing effects:

• Short-term revenue loss when generators cannot be manufactured or delivered.
• Pricing support and customer retention when reliable supply is scarce.

A generator manufacturer with diversified isotope sourcing has a stronger commercial position than one dependent on a single reactor or processor.

Demand is stable but operationally perishable

Technetium-99m demand is relatively predictable at the aggregate market level. Individual doses cannot be inventoried for long because of radioactive decay. Hospitals therefore value delivery reliability, quality consistency, and ordering flexibility.

This reduces the importance of conventional brand marketing. Purchasing decisions are driven more by:

• Delivered activity.
• Elution yield.
• Radionuclide purity.
• Generator reliability.
• Delivery timing.
• Technical service.
• Contract pricing.
• Regulatory continuity.

PET creates a competing technology pathway

PET has expanded in oncology, neurology, and cardiology. Fluorine-18 and other PET isotopes compete with technetium-based SPECT procedures in selected indications.

Technetium retains advantages where:

• SPECT equipment is already available.
• Imaging volumes are high.
• Cost containment is important.
• A generator-based supply model is preferable.
• The clinical protocol is well established.

The competitive threat is therefore gradual substitution, not an immediate collapse in technetium demand.

What companies compete with DRYTEC?

Competition varies by country because generator approvals, isotope sources, and distribution rights are local.

The relevant competitive groups include:

Competitor group	Examples	Competitive basis
Global radiopharmaceutical manufacturers	Curium, Cardinal Health, Lantheus, NorthStar Medical Radioisotopes	Isotope supply, generator technology, distribution, hospital contracts
Integrated nuclear-medicine suppliers	Curium and regional radiopharmacy operators	Generator supply combined with prepared doses
Alternative generator products	TechneGen, TechneLite and other authorized generators	Product specifications, activity range, service, price
Direct cyclotron supply	Regional producers using enriched molybdenum or cyclotron-based technetium routes	Reduced reactor dependence in selected markets
PET alternatives	FDG and other PET tracers	Clinical performance, reimbursement, installed equipment

DRYTEC’s competitive position is strongest where it has active authorization, dependable ^99Mo sourcing, established distribution, and hospital familiarity. A product can lose practical market share without losing regulatory approval if its supplier cannot provide consistent activity levels or delivery schedules.

What patents protect DRYTEC?

The principal commercial protection for DRYTEC is unlikely to come from a currently enforceable, product-specific patent estate. The generator concept and many fundamental technetium-elution technologies are longstanding. Any early patents associated with the generator design, alumina column, shielding, elution system, or radionuclide separation would generally have expired or be approaching expiration after the standard patent term.

Current barriers are more likely to include:

• Regulatory approvals.
• Manufacturing know-how.
• Validated generator assembly processes.
• Quality-control methods.
• Reactor and processor contracts.
• Radioactive-material licenses.
• Distribution infrastructure.
• Customer qualification and switching costs.
• Trademark and product recognition.

Are formulation patents relevant to DRYTEC?

Conventional formulation patents have limited relevance because DRYTEC is a radionuclide generator rather than a finished oral or injectable therapeutic. The commercially important technical protections concern generator architecture, column chemistry, shielding, elution performance, sterile configuration, and production controls.

Are method-of-use patents relevant?

Method-of-use patents are not the main barrier. Technetium-99m is used to prepare multiple diagnostic agents, but most relevant imaging uses are mature and generally rely on established clinical protocols. Product differentiation is primarily operational and regulatory.

When does DRYTEC lose exclusivity?

DRYTEC does not have a single global loss-of-exclusivity date comparable to a branded pharmaceutical tablet. Exclusivity is jurisdiction-specific and may arise from:

• Marketing authorization.
• Data or market exclusivity.
• Product-specific patents.
• Manufacturing approvals.
• Trademark rights.
• Supply contracts.
• Nuclear-material licensing.

The core technology is mature. The commercial moat is therefore based on execution and authorization rather than a long remaining patent term. A competing manufacturer can enter only after obtaining the relevant medicinal-product authorization, isotope supply, manufacturing capability, transport approvals, and local nuclear licenses.

What is the financial trajectory for DRYTEC?

Standalone revenue is not publicly disclosed

DRYTEC financial results are not separately reported in the public filings of its corporate owner or distributor. The product is generally included within broader radiopharmaceutical, medical-isotope, or pharmaceutical segments.

A defensible product-specific revenue forecast cannot be calculated from public filings without unit volumes, average selling prices, market shares, and manufacturing costs.

Directional financial profile

Financial driver	Expected effect on DRYTEC
Technetium procedure volume	Supports recurring demand
Generator pricing	Can rise during isotope shortages
Reactor outages	Creates abrupt volume and revenue risk
Isotope procurement costs	Pressures gross margin
Air and specialized transport	Raises cost per shipment
Hospital purchasing contracts	Limits price increases
PET substitution	Creates long-term volume pressure
Regulatory maintenance	Adds fixed compliance costs
Generator utilization	Determines manufacturing efficiency
Geographic diversification	Reduces dependence on one market

DRYTEC is best characterized as a mature, recurring-revenue diagnostic product with high operational sensitivity. Its revenue trajectory is likely flatter than that of a newly launched branded medicine, while its margin profile can change sharply during isotope shortages, manufacturing interruptions, or transport disruptions.

What financial risks affect the product?

Supply-chain risk

The largest risk is the availability and timely processing of ^99Mo. A generator manufacturer may have confirmed customer demand but still be unable to ship if isotope feedstock is unavailable.

Customer concentration

Large hospital systems, national radiopharmacies, and government-linked procurement programs can exert pricing pressure. Long-term contracts improve volume visibility but can constrain margins.

Technology substitution

PET adoption can reduce technetium procedure volumes in selected indications. This risk is strongest in oncology and cardiology where PET access is expanding.

Regulatory and environmental costs

Radioactive materials require specialized facilities, trained personnel, monitoring, waste management, and transport controls. These costs create a higher fixed-cost base than ordinary pharmaceutical manufacturing.

Product liability and quality risk

Generator failures, excessive molybdenum breakthrough, low technetium yield, sterility failures, or delayed deliveries can disrupt hospital services and trigger regulatory action.

What generic entry risks exist for DRYTEC?

Generic-style entry is possible but difficult. The market does not depend solely on patent expiry. An entrant must demonstrate product quality and secure the upstream isotope supply chain.

The main entry risks are:

• Approval of a comparable generator.
• Validation of radionuclide purity and elution performance.
• Reliable ^99Mo procurement.
• Specialized manufacturing capacity.
• Radioactive shipment capability.
• Hospital and radiopharmacy qualification.
• Local nuclear licenses.
• Commercial-scale production economics.

Paragraph IV litigation is not a central visible risk for DRYTEC in the way it is for a patented small-molecule medicine. A challenger would more likely pursue an independent regulatory authorization than rely on a conventional ANDA patent challenge. Publicly visible Paragraph IV litigation specifically targeting DRYTEC is not a defining feature of the product’s competitive landscape.

What licensing deals and partnerships matter?

The most important commercial arrangements are generally upstream and distribution-based:

• ^99Mo supply agreements with reactor operators and processors.
• Generator manufacturing and technology licenses.
• Regional distribution agreements.
• Radiopharmacy supply contracts.
• Hospital purchasing agreements.
• Transport and radioactive-material handling contracts.

These arrangements can be more valuable than a patent license because uninterrupted isotope supply determines whether the product can be sold. Public company filings typically disclose material transactions at the business-unit level rather than identifying DRYTEC-specific economics.

How does DRYTEC compare with alternative technetium generators?

Metric	DRYTEC	Alternative generators
Core use	Production of ^99mTc for diagnostic imaging	Same
Product maturity	Mature	Mature
Main differentiation	Supply reliability, generator performance, regional authorization	Price, activity range, service, supply
Patent dependence	Limited current relevance	Generally limited for mature platforms
Main barrier	Isotope supply and regulatory infrastructure	Same
Revenue model	Recurring generator shipments	Recurring generator shipments
Key substitute	PET and cyclotron-based routes	PET and cyclotron-based routes

DRYTEC should be evaluated as part of the broader technetium supply network, not as an isolated pharmaceutical brand.

What is the outlook for DRYTEC?

The base case is stable demand with modest long-term pressure from PET substitution and periodic upside from isotope shortages. The product should retain value where hospitals depend on generator-based technetium supply and where alternative production routes are unavailable or uneconomic.

The strongest positive indicators are:

• Stable SPECT procedure volumes.
• Diversified ^99Mo sourcing.
• Reliable generator delivery.
• Active regulatory approvals.
• Long-term hospital and radiopharmacy contracts.
• Low product failure rates.

The principal negative indicators are:

• Repeated reactor outages.
• Loss of a major isotope supplier.
• Declining technetium procedure volumes.
• PET reimbursement expansion.
• Product discontinuation in key jurisdictions.
• Manufacturing or quality failures.

Key Takeaways

• DRYTEC is a ^99Mo/^99mTc diagnostic generator, not a conventional therapeutic drug.
• Its market is mature, recurring, and supply-chain dependent.
• Product-level revenue and profit are not publicly disclosed.
• Current value is driven more by regulatory authorization, isotope access, manufacturing know-how, and distribution than by active patent exclusivity.
• Paragraph IV litigation and conventional generic erosion are not the primary risks.
• Reactor outages and isotope-processing constraints can materially affect supply and pricing.
• PET expansion is the main long-term technology substitution risk.
• The likely financial trajectory is stable to modestly declining procedure-linked demand, with periodic price and margin volatility caused by isotope availability.

FAQs

Is DRYTEC a radioactive drug or a medical device?

DRYTEC is a radionuclide generator used to prepare technetium-99m diagnostic agents. Its regulation combines medicinal-product, radioactive-material, manufacturing, and transport requirements.

Does DRYTEC have a U.S. Orange Book listing?

A conventional U.S. Orange Book listing is not the primary regulatory reference for DRYTEC. The product is mainly associated with non-U.S. and European regulatory frameworks, and its commercial protection does not depend on a standard branded-drug Orange Book patent listing.

Can hospitals replace DRYTEC with PET imaging?

In selected indications, PET can replace or reduce technetium-based SPECT use. Replacement depends on clinical appropriateness, equipment access, isotope availability, reimbursement, and cost.

Is DRYTEC exposed to biosimilar competition?

No. Biosimilars apply to biological medicines. DRYTEC is a radionuclide generator and faces competition from other generators, alternative technetium production routes, and PET tracers.

What is the largest investment risk associated with DRYTEC?

The largest risk is supply-chain disruption involving ^99Mo production, processing, transport, or regulatory authorization. The product’s commercial performance depends on uninterrupted isotope availability.

References

1. International Atomic Energy Agency. (2017). Technetium-99m radiopharmaceuticals: Manufacture of kits. IAEA.
2. Medicines and Healthcare products Regulatory Agency. (n.d.). DRYTEC 99Mo/99mTc generator: Summary of product characteristics. UK electronic Medicines Compendium.
3. World Nuclear Association. (2023). Radioisotopes in medicine. World Nuclear Association.
4. International Atomic Energy Agency. (2021). The supply of medical radioisotopes: An economic diagnosis and regulatory framework. IAEA.